{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:41:22Z","timestamp":1792226482992,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"No external funding was received for the conduct of this study, data analysis, manuscript preparation, or publication","award":["No external funding was received for the conduct of this study, data analysis, manuscript preparation, or publication"],"award-info":[{"award-number":["No external funding was received for the conduct of this study, data analysis, manuscript preparation, or publication"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10072-026-09483-6","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:04Z","timestamp":1792224304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delays in treatment escalation after failure in multiple sclerosis: the role of therapy type and healthcare system"],"prefix":"10.1007","volume":"47","author":[{"given":"Juan I.","family":"Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Liwacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Balbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vrech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Deri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felisa","family":"Leguizamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Luetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mainella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Hryb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Fernandez Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Nadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alonso Serena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Caride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"2","key":"9483_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"10","key":"9483_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Frenay C, Oh J et al (2025) Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 24(10):850\u2013865","journal-title":"Lancet Neurol"},{"issue":"4","key":"9483_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316","journal-title":"Lancet Neurol"},{"issue":"5","key":"9483_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M et al (2019) Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol 76(5):536\u2013541","journal-title":"JAMA Neurol"},{"issue":"2","key":"9483_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96\u2013120","journal-title":"Mult Scler"},{"issue":"10","key":"9483_CR6","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/acn3.70131","volume":"12","author":"P Iaffaldano","year":"2025","unstructured":"Iaffaldano P, Lucisano G, Guerra T et al (2025) Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis. Ann Clin Transl Neurol 12(10):2012\u20132019","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"9483_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP (2024) Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 271(1):105\u2013115","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"9483_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S et al (2016) Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 9(Suppl 1):S5\u2013S48","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"9483_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"SFMSET University of California","year":"2019","unstructured":"University of California SFMSET, Cree BAC, Hollenbach JA et al (2019) Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85(5):653\u2013666","journal-title":"Ann Neurol"},{"issue":"2","key":"9483_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D et al (2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321(2):175\u2013187","journal-title":"JAMA"},{"issue":"3","key":"9483_CR11","first-page":"205521731772084","volume":"3","author":"D Ontaneda","year":"2017","unstructured":"Ontaneda D, Correale J (2017) The challenges and opportunities of multiple sclerosis care in Latin America. Mult Scler J Exp Transl Clin 3(3):2055217317720845","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"9483_CR12","doi-asserted-by":"publisher","first-page":"1685316","DOI":"10.3389\/fimmu.2025.1685316","volume":"16","author":"P Zhao","year":"2025","unstructured":"Zhao P, Guan C, Lu J et al (2025) Global, regional, and national trends and burden of multiple sclerosis in adolescents and young adults: a data analysis from 1990 to 2021 and projections to 2040. Front Immunol 16:1685316","journal-title":"Front Immunol"},{"key":"9483_CR13","doi-asserted-by":"crossref","unstructured":"Rivera VM (2025) Multiple sclerosis: an ethnically diverse disease with worldwide equity challenges accessing care. Neurol Int 18(1)","DOI":"10.3390\/neurolint18010002"},{"issue":"8","key":"9483_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11910-017-0768-4","volume":"17","author":"VM Rivera","year":"2017","unstructured":"Rivera VM (2017) Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep 17(8):57","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"9483_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1352458519898590","volume":"27","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Giachello S, Correale J (2021) Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients. Mult Scler 27(1):117\u2013129","journal-title":"Mult Scler"},{"key":"9483_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.msard.2019.05.024","volume":"33","author":"E Carnero Contentti","year":"2019","unstructured":"Carnero Contentti E, Pettinicchi JP, Lopez PA et al (2019) Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients. Mult Scler Relat Disord 33:88\u201393","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"9483_CR17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 26(14):1816\u20131821","journal-title":"Mult Scler"},{"issue":"1","key":"9483_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12883-025-04106-7","volume":"25","author":"A Beczek","year":"2025","unstructured":"Beczek A, Roikjaer SG, Simony C et al (2025) Experiences and challenges of people with multiple sclerosis and low attendance to clinical follow-up: a qualitative study. BMC Neurol 25(1):107","journal-title":"BMC Neurol"},{"key":"9483_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.msard.2019.05.004","volume":"32","author":"JI Rojas","year":"2019","unstructured":"Rojas JI, Carra A, Correale J et al (2019) The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. Mult Scler Relat Disord 32:133\u2013137","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"9483_CR20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10072-019-04230-6","volume":"41","author":"JI Rojas","year":"2020","unstructured":"Rojas JI, Alonso Serena M, Garcea O et al (2020) Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM). Neurol Sci 41(6):1513\u20131519","journal-title":"Neurol Sci"},{"issue":"17","key":"9483_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA et al (2018) Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(17):777\u2013788","journal-title":"Neurology"},{"key":"9483_CR22","doi-asserted-by":"publisher","first-page":"104485","DOI":"10.1016\/j.msard.2022.104485","volume":"70","author":"V Tkachuk","year":"2023","unstructured":"Tkachuk V, Balbuena Aguirre ME, Alonso R et al (2023) Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort. Mult Scler Relat Disord 70:104485","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"9483_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jhealeco.2004.09.011","volume":"24","author":"WG Manning","year":"2005","unstructured":"Manning WG, Basu A, Mullahy J (2005) Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 24(3):465\u2013488","journal-title":"J Health Econ"},{"issue":"10","key":"9483_CR24","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D et al (2022) Early use of high-efficacy disease\u2013modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382\u20135394","journal-title":"J Neurol"},{"issue":"12","key":"9483_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T (2022) High-Efficacy Therapies for Treatment-Naive Individuals with Relapsing-Remitting Multiple Sclerosis. CNS Drugs 36(12):1285\u20131299","journal-title":"CNS Drugs"},{"issue":"3","key":"9483_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/WNF.0000000000000503","volume":"45","author":"JI Rojas","year":"2022","unstructured":"Rojas JI, Patrucco L, Alonso R et al (2022) Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina. Clin Neuropharmacol 45(3):45\u201351","journal-title":"Clin Neuropharmacol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09483-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:06Z","timestamp":1792224306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09483-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["9483"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09483-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JIR and LP have received reimbursement for developing educational presentations, educational and research grants, consultation fees, and\/or travel stipends from Biogen, Genzyme, Merck, Roche, Biosidus, AstraZeneca, Horizon, Amgen, LACTRIMS, ECTRIMS, The Guthy-Jackson Charitable Foundation, and The Charcot Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ECC has received reimbursement for developing educational presentations, educational and research grants, consultation fees, and\/or travel stipends from Biogen, Genzyme, Merck, Roche, Biosidus, AstraZeneca, Horizon, Amgen, LACTRIMS, ECTRIMS, The Guthy-Jackson Charitable Foundation, The Charcot Foundation, The MOG Project, and The Sumaira Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The RelevarEM registry and the present analysis were performed under the approval of the corresponding Institutional Review Boards\/Ethics Committees of the participating centers. Patient participation and informed consent procedures were conducted in accordance with local regulatory and ethics committee requirements at each participating institution. The present study represents a retrospective analysis of de-identified registry data.","order":3,"name":"Ethics","label":"Ethics approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All other authors declare that they have no conflicts of interest related to this manuscript.","order":4,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"864"}}